Bank of New York Mellon’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-276,411
| Closed | -$4.91M | – | 4316 |
|
|
2018
Q3 | $4.91M | Buy |
276,411
+33,362
| +14% | +$573K | ﹤0.01% | 2426 |
|
|
2018
Q2 | $3.35M | Buy |
243,049
+190,537
| +363% | +$2.26M | ﹤0.01% | 2577 |
|
|
2018
Q1 | $478K | Buy |
52,512
+1,199
| +2% | +$6.62K | ﹤0.01% | 3610 |
|
|
2017
Q4 | $219K | Buy |
51,313
+16,283
| +46% | +$77.6K | ﹤0.01% | 3915 |
|
|
2017
Q3 | $49K | Hold |
35,030
| – | – | ﹤0.01% | 4106 |
|
|
2017
Q2 | $53K | Sell |
35,030
-108,522
| -76% | -$233K | ﹤0.01% | 4124 |
|
|
2017
Q1 | $369K | Buy |
143,552
+6,469
| +5% | +$15K | ﹤0.01% | 3681 |
|
|
2016
Q4 | $350K | Buy |
137,083
+5,537
| +4% | +$15.9K | ﹤0.01% | 3728 |
|
|
2016
Q3 | $406K | Sell |
131,546
-20,466
| -13% | -$63.8K | ﹤0.01% | 3632 |
|
|
2016
Q2 | $488K | Buy |
152,012
+3,561
| +2% | +$13.1K | ﹤0.01% | 3550 |
|
|
2016
Q1 | $460K | Buy |
148,451
+8,379
| +6% | +$27.4K | ﹤0.01% | 3479 |
|
|
2015
Q4 | $562K | Sell |
140,072
-70,686
| -34% | -$326K | ﹤0.01% | 3471 |
|
|
2015
Q3 | $965K | Sell |
210,758
-48,937
| -19% | -$256K | ﹤0.01% | 3209 |
|
|
2015
Q2 | $1.35M | Buy |
259,695
+25,049
| +11% | +$150K | ﹤0.01% | 3173 |
|
|
2015
Q1 | $1.47M | Buy |
234,646
+17,637
| +8% | +$102K | ﹤0.01% | 3072 |
|
|
2014
Q4 | $1.36M | Sell |
217,009
-11,871
| -5% | -$72.4K | ﹤0.01% | 3112 |
|
|
2014
Q3 | $1.39M | Buy |
228,880
+33,530
| +17% | +$229K | ﹤0.01% | 3102 |
|
|
2014
Q2 | $1.29M | Buy |
195,350
+19,371
| +11% | +$218K | ﹤0.01% | 3168 |
|
|
2014
Q1 | $4.19M | Buy |
175,979
+8,456
| +5% | +$123K | ﹤0.01% | 2418 |
|
|
2013
Q4 | $1.79M | Buy |
167,523
+6,102
| +4% | +$67.4K | ﹤0.01% | 2956 |
|
|
2013
Q3 | $2.15M | Buy |
161,421
+10,472
| +7% | +$166K | ﹤0.01% | 2803 |
|
|
2013
Q2 | $1.98M | Buy |
+150,949
| New | +$2.04M | ﹤0.01% | 2794 |
|
Other funds holding ECYT
Bank of New York Mellon's ECYT Position: Q4 2018 in Review
Bank of New York Mellon sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 276,411 shares — an estimated $4.91M sold.
Bank of New York Mellon first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $4.91M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Bank of New York Mellon reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Bank of New York Mellon sold 276,411 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $4.91M.
- Bank of New York Mellon first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Bank of New York Mellon's Endocyte, Inc. Common Stock position peaked at $4.91M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Bank of New York Mellon's 13F filing for Q4 2018, filed 11 Feb 2019.